ClinicalTrials.gg
CompletedNCT02650479Updated Jan 27, 2017

Study of the Effects of Intravenous Exenatide on Cardiac Repolarization

A Phase 1 interventional study of Exenatide and Placebo in Healthy Adult Male and Female Volunteers, sponsored by Intarcia Therapeutics. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-27.

Sponsored by Intarcia Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Two-Part, Randomized, Placebo and Active-Controlled, Double-Blind, Thorough QT Study Evaluating the Effects of Intravenous Exenatide on Cardiac Repolarization in Healthy Male and Female Volunteers

Read the detailed description

This single-center Phase I study will consist of 2 parts, a Pilot Part and a Core Part.

The Pilot Part of the study will be an open-label, non-randomized, single-treatment design in 10 healthy male and female subjects to determine if an infusion regimen of a 6-h continuous IV infusion of exenatide will lead to a mean plasma steady state concentration of 500 pg/mL.

The Core part of the study will be a double-blind (except for the use of open label active control moxifloxacin), randomized, placebo-controlled,3 period, 6-sequence, cross-over design in 72 healthy male and female subjects to evaluate whether exenatide at therapeutic and supra-therapeutic concentrations has a pharmacological effect on cardiac repolarization (threshold value >10 msec).

02

Conditions studied

  • Healthy Adult Male and Female Volunteers
03

In context

Lead sponsor

Intarcia Therapeutics is the lead sponsor of 21 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 19 to 35 kg/m2 inclusive.
  • Women of child bearing potential - use of an additional adequate method of during the study and until 1 additional menstrual cycle following the end-of-study (EOS) visit. Adequate methods of contraception for women of child bearing potential () include: mechanical products (ie, intrauterine device [IUD]-copper IUD); or barrier methods (eg, diaphragm, condoms, cervical cap) with spermacide.
  • (AST), alanine aminotransferase (ALT), alkaline phosphatase (AP), and within normal range at Screening.
  • Fasting triglycerides within the normal range at Screening

Exclusion criteria

Exclusion Criteria:

  • History of type 1 or type 2 diabetes, or history of hypoglycemia.
  • History or evidence of myocardial infarction, congestive heart failure, syncope not related to heart arrhythmia, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention), unstable angina, or cerebrovascular accident or stroke or .
  • History of atrial fibrillation, flutter, or non-sustained or sustained VT.
  • Personal or family history of sudden death or long syndrome.
  • History of uncontrolled hypertension.
  • History or evidence of acute or chronic pancreatitis.
  • History of liver disease.
  • Abnormal renal function.
  • History of medullary thyroid cancer or a personal or family history of multiple endocrine neoplasia type 2.
  • Thyroid-stimulating hormone (TSH) outside of normal limits at Screening .
  • Weight loss surgery.
  • History of (not including basal or squamous cell carcinoma of the skin with past 5 years). (Subjects who have been disease free for greater than 5 years may be included.)
  • History of active alcohol within 1 year prior to Screening.
  • History of drug abuse within 5 years prior to Screening or a positive prestudy drug screen.
  • Weekly consumption of more than 14 alcoholic beverages for females and more than 21 alcoholic beverages for males.
  • Smoke more than 10 cigarettes per day.
  • Excessive in xanthine consumption (more than 5 cups of coffee or equivalent per day).
  • History of to any of the medications used in this study.
  • Women that are pregnant, lactating, or planning to become pregnant.
  • History of or positive results on screening tests for and/or and/or (HIV).
  • History or evidence of status.
  • Prior or current treatment with any GLP-1 receptor agonist (eg, Bydureon™, Byetta®, Victoza®, Tanzeum® or exogenous native GLP-1) or prior participation in an ITCA 650 clinical trial.
  • Any gastrointestinal complaints within 7 days prior to first dosing.
  • Use of medications within 14 days of first dose other than hormone replacement therapy and oral .
  • Chronic (8 consecutive days or greater) treatment with systemic .
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (actual)

Study arms

  • Other
    IV exenatide - pilot study

    IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.

    Drug: Exenatide · Drug: Palonosetron

  • Experimental
    Treatment Group A - core study

    IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.

    Drug: Exenatide · Drug: Palonosetron

  • Experimental
    Treatment Group B - core study

    IV infusion of placebo over 6 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.

    Drug: Placebo · Drug: Palonosetron

  • Experimental
    Treatment Group C - core study

    IV infusion of placebo over 6 hours and a single oral dose of 400 mg moxifloxacin within 1 min of start of infusion, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.

    Drug: Placebo · Drug: Moxifloxacin · Drug: Palonosetron

Interventions

  • 6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).

  • DrugPlacebo

    6 hour IV infusion.

  • 400 mg oral dose moxifloxacin within 1 min of start of infusion of exenatide

  • 0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide

06

What researchers measure

Primary outcomes

  1. Pilot Study: Establishment of mean plasma steady state concentration of 500 pg/mL

    Time frame: 35 days

  2. Core Study: Changes to QTc interval changes (threshold > 10 msec) measurements

    Time frame: 56 days

Secondary outcomes

  1. Pilot Study: Adverse events as assessed by subjective subject reporting, laboratory testing, ECG, physical examinations, and vital signs

    Time frame: 35 days

  2. Core Study: Measurement of exenatide plasma concentrations and relationship to changes in QTc interval measurements

    Relationship between plasma concentrations of exenatide and QTc interval.

    Time frame: 56 days

  3. Core Study: Changes in PR, RR, QRS, QT, T- and U- wave morphology

    Time frame: 56 days

  4. Core Study: Measurement of QTc interval changes moxifloxacin as active control

    Time frame: 56 days

  5. Core Study: Adverse events as assessed by subjective subject reporting, laboratory testing, ECG, physical examinations, and vital signs

    Time frame: 56 days

  6. Pilot Study: Maximum concentration (CMax) of exenatide

    Time frame: 35 days

  7. Pilot Study: Time to maximum concentration (TMax) of exenatide

    Time frame: 35 days

  8. Pilot Study: Area under the curve (AUC) of exenatide

    Time frame: 35 days

  9. Pilot Study: Steady state concentration (Css) of exenatide

    Time frame: 35 days

  10. Pilot Study: Half life (T1/2) of exenatide

    Time frame: 35 days

  11. Core Study: Half life (T1/2) of exenatide

    Time frame: 56 days

  12. Core Study: Steady state concentration (Css) of exenatide

    Time frame: 56 days

  13. Core Study: Area under the curve (AUC) of exenatide

    Time frame: 56 days

  14. Core Study: Maximum concentration (CMax)

    Time frame: 56 days

  15. Core Study: Time to maximum concentration (TMax) of exenatide

    Time frame: 56 days

07

Study locations

1 site
  • PRA-Groningen
    Groningen, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2016
First posted
Jan 8, 2016
Start
Jan 2016
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Last update
Jan 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02650479
Responsible party
Sponsor
First posted
Jan 8, 2016
Start date
Jan 2016
Primary completion
Apr 2016
Completion
Apr 2016
Last update
Jan 27, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Exenatide · Moxifloxacin

Start the discussion